• where experts go to learn about FDA
  • Hyman Phelps McNamara

    • HP&M Promotes James Valentine to DirectorOctober 17th, 2022

      Hyman, Phelps & McNamara, P.C. (HP&M) is pleased to announce that James E. Valentine will become the firm’s newest Director beginning on January 1, 2023.  James’s practice focuses on regulatory considerations for developing new drug and biologic products and FDA regulatory requirements for approval/licensure.  James has been …

    • FDAnews Webinar: Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and AnalysisSeptember 13th, 2022

      Hyman, Phelps & McNamara, P.C.’s Deborah Livornese will be a panelist for FDAnews’ September 15, 2022 webinar titled “Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis”.  Aspirational only title notwithstanding, you can find more information about the webinar and registration at FDAnews and …

    • ACI’s Paragraph IV Disputes Master Symposium – September 21-22, 2022 (Chicago)August 5th, 2022

      Join members of the Judiciary and leading pharmaceutical patent litigators from brand name and generic drug companies at the American Conference Institute’s 8th Annual Paragraph IV Disputes Master Symposium taking place September 21-22, 2022, in Chicago! As the industry prepares to address the fallout of global …

    • ACI’s FDA Boot Camp – September 14-15, 2022 (Virtual)August 5th, 2022

      The American Conference Institute is hosting their 39th FDA Boot Camp from September 14-15, 2022.  The conference will be held virtually. Gain insight and training in core regulatory concepts for life sciences attorneys, business executives, and policy analysts. The approval process, pre-approval concerns, product labeling, clinical trials, …

    • 10th Annual Legal, Regulatory & Compliance Forum on Dietary Supplements is Just Days AwayJune 24th, 2022

      The American Conference Institute and Council for Responsible Nutrition are hosting the 10th Annual Legal, Regulatory & Compliance Forum on Dietary Supplements live in New York next week, June 29-30. The conference will feature speakers from government and industry who will provide updates on the …

    • HP&M’s Dara Katcher Levy to Present at DIA 2022 Global Annual Meeting on Healthcare Economic InformationJune 16th, 2022

      Hyman, Phelps & McNamara, P.C.’s Dara Katcher Levy will be presenting at the DIA 2022 Global Annual Meeting being held this June 19-23 in Chicago, IL.  Dara will be joining an expert panel as part of the Medical Affairs and Scientific Communications Track to discuss manufacturer communications …

    • HP&M’s James Valentine & Ellis Unger @ DIA 2022: FDA Rare Disease Town Hall with CDER & CBER Center Directors, Optimizing Benefit-Risk Assessments, Reflecting on 10 Years of PFDDJune 3rd, 2022

      Hyman, Phelps & McNamara, P.C.’s James Valentine and Ellis Unger will be presenting at the DIA 2022 Global Annual Meeting held this June 19-23 in Chicago, IL.  This meeting brings together industry, regulators, academics, and patients to discuss global and local challenges in the life …

    • The FDLI Annual Conference is Back Live!June 1st, 2022

      On June 14-15 in Washington, DC, the Food and Drug Law Institute (FDLI) will hold its first in-person Annual Conference since 2019.  The conference brings together leading regulators and a wide range of stakeholders to discuss current issues and trends of importance to FDA-regulated industries.  …

    • HP&M’s Sara Koblitz to Present at DC Bar’s FDA for IP Lawyers WebinarMay 23rd, 2022

      Hyman, Phelps, and McNamara’s Sara Koblitz will be presenting at the DC Bar’s annual webinar, “FDA for IP Lawyers” on May 25, 2022 with Brian Malkin of McDermott, Will, and Emery. The webinar will provide practical tips for integrating FDA regulatory law into IP law practices …

    • HP&M Seeks Junior to Mid-Level Associate: Litigation/Internal InvestigationsMay 17th, 2022

      Hyman, Phelps & McNamara, P.C. (HP&M) seeks to add a 2nd to 5th year associate to its enforcement and litigation team.  Our team investigates and defends against threatened enforcement actions by government prosecutors and regulators, including the FDA and DEA.  Types of matters include: Representing clients in …

    • HP&M’s Sophia Gaulkin to Present on Drug Pricing at Advanced Summit on Life Sciences PatentsMay 5th, 2022

      Hyman, Phelps & McNamara, P.C. is pleased to announce that Sophia Gaulkin will be speaking on an expert panel at the 20th Advanced Summit on Life Sciences Patents, which is being held virtually and in-person in New York City on June 2-3, 2022. Ms. Gaulkin will join speakers …

    • ACI’s 17th Annual Paragraph IV Disputes Conference (In-Person and Livestream)April 14th, 2022

      The American Conference Institute (“ACI”) is hosting its 17th Annual Paragraph IV Disputes Conference in New York (and livestream) from April 26-27, 2022 (Eastern Daylight Time).  Over the course of two days, this event will provide impactful and practical programming all geared towards assessing the implications and …

    • James R. Phelps: 1938 – 2022April 4th, 2022

      With great sadness, we announce that our firm’s co-founder, leader, colleague and friend, Jim Phelps passed away on April 2, 2022, at the age of 83. Jim is survived by Sophia, his wife of 57 years, his three sons and their wives, Evan and Nicola, …

    • HP&M’s Sophia Gaulkin to Present on Changes to State Drug Pricing Transparency RequirementsMarch 17th, 2022

      Hyman, Phelps & McNamara, P.C. is pleased to announce that Sophia Gaulkin will be presenting and speaking on an expert panel at Informa Connect’s Drug Pricing Transparency Congress, which is being held virtually and in-person in Philadelphia on March 28-29, 2022. Ms. Gaulkin’s presentation on Changes …

    • We are hiring! HP&M Seeks Mid-Level FDA Regulatory AttorneyJanuary 10th, 2022

      Hyman, Phelps & McNamara, P.C. is the largest dedicated FDA law firm, and we need attorneys to help our clients bring pharmaceutical drugs and medical devices to market.  Our ideal candidates have experience working at FDA (CDER, CDRH, CBER, or OCC), or have at least …